The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Biocon has reported consolidated financial results for the period ended December 31, 2021
They will commercialize molnupiravir in the international markets
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Subscribe To Our Newsletter & Stay Updated
